Novartis will review data from its ongoing research collaboration with BioArctic before deciding whether to exercise an option to license any drug candidate developed under the agreement. If the option is exercised, BioArctic could receive milestone payments of up to USD 772 million, in addition to tiered mid-single-digit royalties on future global product sales should the therapy reach the market.

The partnership focuses on combining BioArctic’s BrainTransporter technology with a Novartis proprietary antibody to develop a novel drug candidate. Should Novartis proceed, it would take full responsibility for the candidate’s global development and commercialization.

Gunilla Osswald, CEO of BioArctic, said, “Novartis shares our passion for science and helping patients with severe neurological disorders. With another BrainTransporter collaboration, it’s evident this versatile platform holds enormous potential to advance treatments across multiple projects and therapeutic areas.”

Sophie Parmentier Batteur, Head of Neurodegeneration Research at Novartis, added, “Collaborating with BioArctic allows us to explore the BrainTransporter’s ability to enhance brain uptake and optimize delivery of novel therapies. Our goal is to pioneer treatments that can alter disease progression and meaningfully impact patients’ lives.”

This marks BioArctic’s third BrainTransporter partnership. The company retains rights to use the platform in other areas, keeping open additional opportunities for future collaborations across biologics and novel modalities.